ArticleBone marrow transplantation2010
Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: effects on infectious complications and early transplant outcomes.
Article in Bone marrow transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.Frontiers in immunology · 2024Pooled it
- Pooled it
- Trial
- Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs.Bone marrow transplantation · 2012Trial
- Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.European journal of haematology · 2026Article
- Financial Toxicity of Hematologic Malignancy Therapies, Including Cellular Therapy and Its Impact on Access to Care: Prospective Pilot Study.JMIR cancer · 2026Observational
- Efficacy and safety of air-flow beds for autologous hematopoietic stem cell transplantation in multiple myeloma: a retrospective cohort study.Frontiers in oncology · 2026Article
- Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective.Blood advances · 2024Article
- Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience.Frontiers in immunology · 2024Review
- Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies.Frontiers in immunology · 2024Review
- Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy.Frontiers in oncology · 2024Review
- Outpatient allogeneic hematopoietic stem-cell transplantation: a review.Therapeutic advances in hematology · 2022Review
- Exploring the caregiver's experience in an innovative homebound hematopoietic stem cell transplantation program.Palliative & supportive care · 2021Article
- Article
- A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe.Bone marrow transplantation · 2020Article
- Caregiver availability and patient access to hematopoietic cell transplantation: social worker perspectives inform practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study.BMC infectious diseases · 2019Article
- Bloodstream infection in hematopoietic stem cell transplantation outpatients: risk factors for hospitalization and death.Revista do Instituto de Medicina Tropical de Sao Paulo · 2018Article
- High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.BMC cancer · 2017Article
- A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions.Bone marrow transplantation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective single-center study compared the incidence, spectrum and effect of infections in 1045 consecutive allogeneic (allo) and autologous (auto) hematopoietic SCT (HSCT) performed between 1995 and 2006 in the inpatient (IP) or outpatient (OP) setting. We analyzed 374 allo-HSCT (196 IP and 178 OP) and 671 auto-HSCT (163 IP and 508 OP). The incidence of infection was lower both in auto-OP (25% OP vs 33% IP, P=0.042) and allo-OP cohorts (42.7% OP vs 55.6% IP, P=0.012). The mean number of infections per transplant was lower in both auto-OP (0.39 OP vs 0.57 IP, P=0.05) and in allo-OP cohorts (0.78 OP vs 1.09 IP, P=0.018). The 100-day non-relapse mortality (NRM) for OP auto-HSCT was 4.72% and for IP 3.95% (P=0.68). The 100-day NRM for OP allo-HSCT was lower at 14.1% than it was for IP at 22.6% (P=0.041). Time to onset of first infection and spectrum of infections was similar in all groups. We conclude that performing allo- and auto-HSCT in the OP setting results in short-term outcomes, including infections complications that are comparable to the standard IP setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.